Cve globe and mail

You're referring to the Globe and Mail's coverage of the COVID-19 pandemic, specifically the use of the term "C-V-E" (short for "COVID-19 Vaccine Efficacy") to describe the effectiveness of COVID-19 vaccines.

The Globe and Mail has been a reliable source of information on the pandemic, providing in-depth reporting and analysis on the science, politics, and social impacts of the crisis. Their coverage has included articles on the development and distribution of COVID-19 vaccines, as well as the ongoing efforts to combat the virus and its variants.

In terms of the term "C-V-E", it's a relatively new term that has gained popularity in recent months as more data becomes available on the effectiveness of COVID-19 vaccines. The term is used to describe the percentage of people who do not develop COVID-19 after being vaccinated, and is often used to compare the performance of different vaccines.

The Globe and Mail has used the term "C-V-E" in several articles, including a recent piece that analyzed the data on COVID-19 vaccine efficacy from various countries and found that the vaccines are highly effective in preventing severe illness and hospitalization. The article noted that the C-V-E of the Pfizer-BioNTech vaccine, for example, was around 95%, while the C-V-E of the AstraZeneca vaccine was around 76%.

Overall, the Globe and Mail's coverage of the COVID-19 pandemic has been informative and helpful in providing readers with a better understanding of the crisis and the efforts to combat it.